A detailed history of Quantbot Technologies LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Quantbot Technologies LP holds 282 shares of CRNX stock, worth $11,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282
Holding current value
$11,105
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$43.83 - $54.98 $12,360 - $15,504
282 New
282 $14,000
Q3 2022

Nov 07, 2022

BUY
$18.11 - $22.37 $1,792 - $2,214
99 New
99 $1,000
Q1 2022

May 16, 2022

SELL
$17.15 - $28.31 $87,910 - $145,117
-5,126 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$19.35 - $28.41 $33,398 - $49,035
1,726 Added 50.76%
5,126 $145,000
Q3 2021

Nov 09, 2021

BUY
$16.88 - $25.23 $45,576 - $68,121
2,700 Added 385.71%
3,400 $71,000
Q2 2021

Aug 12, 2021

BUY
$15.9 - $21.15 $11,130 - $14,804
700 New
700 $13,000

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.12B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.